Publications from SPCG

1. Papers in Medical Journals
2. Dissertations
3. Other papers
4. Oral presentations or Posters including abstracts.

Updated on 28-10-2007

A. Papers in Medical Journals

1. 1. Hörder M, Rasmussen F (Eds) Acid phosphatases and other tumour markers in the management of
   prostate cancer. Scand J Clin Invest (suppl 179) 1985; 45.
2. Iversen P. (ed.) Carcinoma of the Prostate, views and recommendations. Scand J Urol Nephrol
   1991; 25: (suppl 139):1-63.
3. Hedlund PO, Esposti P, Falkmer U, Jacobsen H. DNA as a prognostic marker in advanced highgrade
   prostatic cancer. A preliminary report. SPCG-1 study. Acta Oncol 1991;30(2):215-217.
4. Jørgensen T, Tveter KJ, Jørgensen LH, SPCG-2 group. Total androgen suppression: Experience
   from the Scandinavian Prostate Cancer Group Study No. 2. Eur Urol 1993;24:466-470.
5. Iversen P, Adolfsson, Johansson JE, Torp-Pedersen S. Localized prostate cancer - A Scandinavian
   View. Monographs in Urology 1994;15:93-112.
6. Jørgensen T, Müller C, Kaalhus O, Danielsen HE, Tveter KJ. Extent of disease based on initial
   bone scan: Important prognostic predictor for patients with metastatic prostatic cancer. Experience
   from the Scandinavian Prostatic Cancer Group Study no 2 (SPCG-2). Eur Urol 1995; 28: 40-46.
7. Jørgensen T, Yogesan K, Skjørten F, Berner A, Tveter KJ, Danielsen HE. Histopathological
   grading and DNA ploidy as prognostic markers in metastatic prostatic cancer. Br J Cancer
   1995;71:1055-1060.
8. Jørgensen T, Berner A, Kaalhus O, Tveter KJ Danielsen HE, Bryne M. Up-Regulation of the
   Oligoaccharide Sialyl Lewis-x: A New Prognostic Parameter in Metastatic Prostate Cancer. Cancer
   Research 1995;55:1817-1819.
9. Jørgensen T, Yogesan K, Tveter KJ, Skjorten F, Danielsen HE. Nuclear texture analysis: a new
   prognostic tool in metastatic prostate cancer. Cytometry 1996 24(3):277-283.
10. Hedlund PO, Jacobsen H, Vaage S, Hahne B, Sandin T, Kontturi M, Nordle Ö, Esposti P and the
    SPCG-1-Study Group. Treatment of High-grade, High-stage Prostate Cancer with Estramustine
    Phosphate or Diethylstilbestrol. Scand J Urol Nephrol 1996;31:167-172.
11. Hedlund PO and the SPCG Group. The Scandinavian Prostatic Cancer Group. Editorial. Scand J
    Urol Nephrol 1997;31:5-7.
12. Iversen, P. on behalf of the Scandinavian Prostatic Cancer Group. Combined Androgen Blockade in
    the Treatment of Advanced Prostatic Cancer – An overview. Scand J Urol Nephrol 1997;31:249-
    254.
13. Jørgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen
    HE. Prognostic factors in patients with metastatic (stage D2) prostate cancer: Experience from the
    Scandinavian Prostatic Cancer Group Study-2. J Urol 1997;158:164-170.
14. Hedlund PO, Henriksson P, and the Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Parenteral Estrogen versus Total Androgen Ablation in the Treatment of Advanced Prostate
    Carcinoma: Effects on Overall Survival and Cardiovascular Mortality. Urology 2000;55:328-333.
15. Spetz A-C, Hammar M, Lindberg B, Spångberg A, Varenhorst E and the Scandinavian Prostatic
    Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral
    estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol
    2001;166:517-520.
16. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide early prostate cancer program
    demography. Urologic Oncology 2001;6:43-47.
17. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell
    C, Wallace DMA, Delaere KPJ, Vaage S, Tammela TLJ, Lukkarinen O, Persson B-E, Carroll K,
    Kolvenbag GJCM on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide as
    immediate therapy either alone or as adjuvant to standard care of patients with localized or locally
    advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002;168:429-
    435.
18. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson S-O,
    Spångberg A, Busch C, Nordling S, Palmgren J, Adami H-O, Johansson J-E, Norlén BJ for the
    Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical
    prostatectomy with watchful waiting in early prostate cancer. N Eng J Med 2002;347:781-789.
19. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson J-E, Norlén BJ, Holmberg L for the
    Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after Radical Prostatectomy
    or Watchful Waiting. N Eng J Med 2002;347:790-796.
20. Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P,
    Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K, Scandinavian Prostatic Cancer
    Group (SPCG). A Randomised Comparison of Bicalutamide (“Casodex”) 150 mg versus Placebo
    as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic
    Prostate Cancer. First report from the Scandinavian Prostatic Cancer Group Study no. 6. European
    Urology 2002;42:204-211.
21. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson
    P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E and the SPCG-5 Study
    Group. Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic
    Prostatic Cancer. Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol
    2002;36:405-413.
22. Wirth M, Iversen P, Mcleod D, See W. Immediate therapy in early prostate cancer: Results from
    the bicalutamide (Casodex) EPC Programme. Eur Urol Suppl 2002; 1(7):20-25.
23. Iversen P, Newling D, Kirby R, Eadrley I. Sexual function: quality of life issues in patients with
    locally advanced non-metastatic prostate cancer. Eur Urol Suppl 2002;1(7):26-32.
24. Widmark A, Fosså SD, Lundmo P, Damber J-E, Vaage S, Damber L, Wiklund F, Klepp O. Does
    prophylactic breast irradiation prevent antiandrogen induced gynecomastia? Evaluation of 253
    patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003;61:145-151.
25. See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with
    bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early
    prostate cancer. Eur Urol 2003;44:512-518.
26. Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol Suppl.
    2003;170 (6):S48-S54.
27. Payne H, Tyrrell CJ, See WA, McLeod DG, Wirth MP, Iversen P, Garside L. Bicalutamide 150 mg as
    adjuvant to radiotherapy significantly increases progression-free survival in early prostate cancer. Int J
    Radiat Oncol Biol Phys 2003; 57 (2 suppl): 173-174.
28. Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell
    C, Wallace DMA, Delare KPJ, Lundmo P,Tammela TLJ, Johansson J-E, Morris T, Carrol K, ON
    Behalf of the Casodex Early Prostate Cancer Trialist Group. Is the efficacy of hormonal therapy
    affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer
    Program. Urology 2004;63:928-933.
29. Wirth M, See WA, McLeod D, Iversen P, Morris T, Carrol C, The Casodex Early Prostate Cancer
    Trialist Group. Bicalutamide 150 mg in addition to standard care in patients with localized or
    locally advanced prostate cancer: results from the second analysis of the early prostate cancer
    program at median followup of 5.4 years. J Urol 2004;172(Part 1):1865-1870.
30. Iversen P, Johansson Jan-Erik, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TLJ,
    Tasdemir I, Morris T, Carrol K, The Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg)
    versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early
    nonmetastatic prostate cancer: 5.3-year median followup from The Scandinavian Prostate Cancer
    Group Study number 6. J Urol 2004;172(Part 1):1871-1876.
31. Jønler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, Waldén M, & the
    Sandinavian Prostate Cancer Group Study 5 Study Group. Quality of life in patients with skeletal
    metastases of prostate cancer. Status prior to start of endokrine therapy. Results from the
    Scandinavian prostate Cancer Group study 5. Scand J Urol Nephrol 2005;39:42-48.
32. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson S-O, Bratell S, Spångberg A,
    Busch C, Nordling S, Garmo H, Palmgren J, Adami H-O, Norlén BJ, Johansson, J-E for the
    Scandinavian Prostate Cancer Study Group Study No. 4. Radical Prostatectomy versus Watchful
    Waiting in Early Prostate Cancer. N Eng J Med 2005;352:1977-1984.
33. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C.
    Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally
    advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
    Radiother Oncol. 2005 Jul;76(1):4-10.
34. Stranne J, Hugosson J, Iversen P, Morris T, Lodding P. Inguinal hernia in stage M0 prostate cancer:
    a comparison of incidence in men treated with and without radical retropubic prostatectomy - an
    analysis of 1105 patients. Urology 2005; 65: 847-851.
35. Mcleod,David G.; Iversen,Peter; See,William A.; Morris,Thomas; Armstrong,Jon; Wirth,Manfred
    P.; on behalf of the Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus
    standard care vs standard alone for early prostate cancer. BJU Internat 2006;97:247-254.
36. Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela T, Tasdemir I,
    Morris T, Amstrong J. Bicalutamide 150 mg in addition to standard care for patients with early
    non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Group
    Study-6 after a median follow-up period of 7.1-years. Scand J Urol Nephrol 2006;40:441-452.
37. Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén HB, Adami H-O, Johansson J-E.
    Scandinavian Prostate Cancer Group study No 4. Prognostic markers under watchful waiting and
    radical prostatectomy. Hematology/Oncology Clinics of North America 2006;20:845-856.
38. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P. Prognostic value
    of serum PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate
    carcinoma. The Prostate 2006; 66(5): 503-513.
39. Warren KS, Chodak GW, See WA, Iversen P, McLeod D, Wirth M, Morris C, Armstrong J. Are bone
    scans necessary in men with low prostate specific antigen levels following localized therapy? Journal
    of Urology 2006; 176(1): 70-73.
40. Iversen P. The third analysis of the bicalutamide early prostate cancer programme. British Journal of
    Urology International 2006; 97(3): 438-439.
41. Fall K, Garmo H, Andrén O, Bill-Axelson, Adolfsson J, Adami H-O,Johansson J-E, Holmberg L.
    Prostate-specifik antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:626-
    532.
42. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ. Changes of
    Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic
    Prostate Cancer Are Related to Survival. Clin Cancer Res 2007;13:3244-3249.

B. Dissertations

1. Jørgensen T. Prognostic factors in metastatic prostate cancer. Experience based on the
   Scandinavian Prostatic Cancer Group Study no 2. Thesis. Norwegian Cancer Society, Oslo 1999.
2. Anna Bill-Axelsson. Localized Prostate Cancer. Results from a Randomized Clinical Trial. Thesis
   Uppsala University. Acta Universitatis Upsaliensis 2005. ISBN 91-554-6206-5.

C. Other papers

1. Rasmussen, F. Scandinavian Prostatic Cancer Group. Ugeskr Læger 1983;145:xxix.
2. Rasmussen F. Scandinavian Prostatic Cancer Group (SPCG). (Editorial) Ugeskr Læger
   1985;147:1950.
3. SPCG. Cancer prostatae. April 1983. Booklet with recommendations on grading, staging,
   categories, response criteria and control forms.
4. Rasmussen F, Krarup T. Scandinavian Prostatic Cancer Group. De første 10 år. Paper on meetings
   during the first 10 years.
5. Hedlund PO, Hugosson J, Iversen P. Är bot möjlig - är bot nödvendig? NUF Bulletinen, December
   1994; 9-11.
6. Iversen P. Rapport fra SPCG. NUF-Bulletinen Summer 1998:15-16.
7. SPCG’s 20-year anniversary at Soria Moria, Oslo, February 16th, 2002. Scand J Urol Nephrol;37
   Suppl 212:1-40.
• Heikkilä R, Hedlund PO for the ordinary and affiliated members of the SPCG. In memoriam
  Sigmund Vaage, 133-2003. Scand J Urol Nephrol 2003;37 Suppl 212:3.
• Vaage S. Introduction. Scand J Urol Nephrol;37 Suppl 212:5-6.
• Høisæter PÅ, Vaage S, Hedlund PO. Clinical Research Done by the Scandinavian Prostate
  Cancer Group during the First 20 Years. Scand J Urol Nephrol;37 Suppl 212:7-11.
• Vaage S. Radical Treatment of Organ-localized and Locally Advanced Prostate Cancer in
  Norway. Scand J Urol Nephrol;37 Suppl 212:11-15.
• Newling DWW. Immediate or Deferred Hormonal Therapy? Scand J Urol Nephrol;37 Suppl
  212:16-19.
• Nisen P. New Principles in the Treatment of Hormonal Refractory Prostate Cancer. Scand J
  Urol Nephrol;37 Suppl 212:20-22.
• Widmark A. New Principles in the Treatment of Prostate Cancer. The Oncologist’s View.
  Scand J Urol Nephrol;37 Suppl 212:23-27.
• Hansson J, Abrahamsson P-A. Neuroendocrine Differentiation in Prostate Carcinoma. Scand J
  Urol Nephrol;37 Suppl 212:28-36.
• Øgreid P, Kvalheim G. old and New Research into Micometastases in Prostate Cancer. Scand J
  Urol Nephrol;37 Suppl 212:37-39.
• Vaage S. Concluding Remarks. Scand J Urol Nephrol;37 Suppl 212:40.

D. Oral presentations or Posters including abstracts.

1. Tveter KT, Jørgensen T and members of the Scandinavian Prostatic Cancer Group. Total androgen
   suppression in metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer
   Group. Poster & podium presentation at the SIU Congress in Seville November 1991.
2. Helgesen F, Holmberg L, Johansson J-E, Adami H-O, Norlén B-J. Radical prostatectomy versus
   watchful waiting in localized prostate cancer. A randomized multicentre study. Early presentation
   of an ongoing study. Oral presentation at the 21st Congress of the Scandinavian Association of
   Urology Copenhagen May 1997. Abstract in Scand J Urol Nephrol 1997;31 Suppl.186:30-31.
3. Iversen P. SPCG 6 - early antiandrogen therapy versus placebo in non-metastatic prostate cancer.
   Scandinavian Prostatic Cancer Group - Research Meeting, Copenhagen, March 1998. Invited
   presentation.
4. Wirth MP, Iversen P. A clinical programme consisting of 3 randomised, double blind, parallelgroup
   trials comparing bicalutamide (Casodex) 150 mg daily with placebo in patients with nonmetastatic
   cancer: Preliminary demography data from one of the largest international early prostate
   cancer programmes. Poster presentation, EAU, XIIIth Congress, Barcelona, Spain, March 1998.
   Abstract in Eur Urol 1998;33 Suppl 1:136. Abstract 541.
5. Iversen P, Tyrell C, Kaisary A, Anderson J, Baert L, Tammela T, Chamberlain M, Wirth M,
   Mcleod D, See W. Prospects for improving survival in early prostate cancer: results and ongoing
   studies with the non-steroidal antiandrogen bicalutamide (Casodex). Poster presentation AUA San
   Diego May 1998. Abstract 1301 in J Urol 1998;159:338.
6. Wirth M, Iversen P, See W, McLeod D et al. Bicalutamide [Casodex] Early Prostate Cancer (EPC)
   Programme: Final demographic data from over 8000 randomised patients. Poster presentation.
   European Association of Urology. XIVth Congress, Stockholm, April 1999. Abstract 52 in Eur
   Urol 1999;35 Suppl 2:196.
7. Iversen P. A controlled randomised comparison of bicalutamide (Casodex) with placebo in early
   prostate cancer. Final demographic data from over 8000 patients worldwide. Second International
   Consultation of Prostate cancer. Patronized by WHO and UICC. Paris, France. June 1999. Invited
   presentation.
8. Hedlund PO, Haukaas S, Rasmussen F, Salo J, Varenhorst for the SPCG-5 Study Group. Parenteral
   estrogen vs combined androgen deprivation in the treatment of advanced prostate cancer. Oral
   presentation at the 22nd Congress of the Scandinavian Association of Urology, Reykjavik June
   1999. Abstract in Scand J Urol Nephrol 1999;33 Suppl 200:11.
9. Fourcade RO, Wirth M, See WA, McLeod DG, Iversen P. Le Programme “Bicalutamide EPC”:
   Resultats Démographiques de 8113 patients Randomisés. 93rd Congres Francais D’Urologie Paris
   Nov 1999. Abstract in Progres en Urologie 1999;9(5) Suppl 1:P21.
10. Hedlund PO, Frimodt-Møller C, Johansson J-E, Klarskov P, Lindeborg T and the SPCG-5 Study
    Group. Parenteral estrogen therapy in prostate cancer. 25th SIU World Congress Singapore Nov.
    2000. Abstract in BJU International 2000;86 (Suppl. 3):221.
11. McLeod D, See W, Iversen P, Wirth M, Beckman R, Carroll K. Tolerability of bicalutamide
    (“Casodex”) 150 mg as immediate or adjuvant therapy in 8113 men with localized or locally
    advanced prostate cancer. Annual Meeting of the American Society of Clinical Oncology San
    Francisco May 2001. Proc ASCO 2001;20(2):p154b. Abstract 2366.
12. Wirth M, See W, McLeod D, Iversen P, Persson B-E, Carroll K. Bicalutamide (“Casodex”) 150
    mg) as Immediate Or Adjuvant Therapy in 8113 Men With Localised Or Locally Advanced
    Prostate Cancer. Poster presentation Annual Meeting of the American Society of Clinical Oncology
    May 2001. Abstract in Proc ASCO 2001;20:177a. Abstract 705.
13. McLeod D, See W, Iversen P, Wirth M, Beckman R, Carroll K. Tolerability of bicalutamide
    (“Casodex” 150 mg) as immediate or adjuvant therapy in 8113 men with localized or locally
    advanced prostate cancer. Podium presentation AUA Anaheim California June 2001. Abstract 617
    in J Urol 2001; 165 Suppl S:150.
14. See W, McLeod D, Wirth M, Iversen P, Persson B-E, Carroll K. Bicalutamide (“Casodex”) 150
    mg) as Immediate or adjuvant therapy in 8113 men with localised or locally advanced prostate
    cancer. Podium presentation AUA Anaheim California June 2001. Abstract 1594 in J Urol
    2001;165 Suppl S:389.
15. Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Sander S, Viitanen J, Hoisaeter PA,
    Lundmo P, Rasmussen F, Persson B-E, Carrol K on behalf of the SPCG-6 study group. SPCG-6:
    Bicalutamide vs. placebo in early nonmetastatic prostate cancer. Scandinavian Urological
    Association of Urology 23rd Congress, 24th. August 2001, Helsinki. Abstract 34 in Scand J Urol
    Nephrol 2001; 35, Suppl. No. 208: 26-27.
16. Tyrell C, Payne H, Wirth M, Iversen P, See W, McLeod D, Persson B-E, Carroll K. Bicalutamide
    (“Casodex”) 150 mg as adjuvant to radiotherapy in localised or locally advanced prostate cancer.
    Podium presentation ECCO Annual Meeting Lisbon Portugal October 2001. Abstract 571 in Eur J
    Cancer 2001;37suppl 6:S157.
17. Lundmo PI, Vaage S, Sander S, Højsæter PÅ, Iversen P, Rasmussen F, Tammela T, Lukkarinen O,
    Viitanen J, Lodding P, Persson B-E, Carroll K, SPCG-6 study group. SPCG-6: Bicalutamide versus
    placebo ved ikke-metastaserende prostatakreft. Norsk Urologisk Selskabs efterårsmøte, October
    2001.
    
18. Tyrell C, Payne H, Wirth M, , Iversen P, See W, McLeod D, Persson B-E, Carroll K. Bicalutamide
    (“Casodex”) 150 mg) as adjuvant to radiotherapy in localised or locally advanced prostate cancer.
    Podium presentation American Society of Therapeutic Radiology and Oncology (ASTRO) Annual
    meeting San Francisco, USA, November 2001.
    
19. Iversen P. Bicalutamide in early prostate cancer. Top line summary of original data. US
    International Early Prostate cancer Workshop. Boca Raton, Florida, USA. January 2002. Invited
    presentation.
20. Iversen P, Wirth M, See W, McLeod D, Morris T, Carroll K on behalf of the “Casodex” Early
    Prostate Cancer Trialists’ Group. Is the efficacy of hormonal therapy affected by lymph node
    status? New data from the bicalutamide EPC programme. Podium presentation EAU Birmingham
    February 2002. Abstract 528 in Eur Urol 2002; 1(1):134.
    
21. See W, Wirth M, McLeod D, Iversen P, Persson B-E, Carroll K on behalf of the “Casodex” Early
    Prostate Cancer Trialists’ Group. Immediate treatment with bicalutamide reduces the risk of disease
    progression in early non-metastatic prostate cancer irrespective of primary therapy. Podium
    presentation EAU Birmingham February 2002. Abstract 533 in Eur Urol 2002;1(1):136.
    
22. Iversen P. Bicalutamide 150 mg monotherapy and the first results of the Early Prostate Cancer
    programme including 8,113 patients. 24th Biennial Congress of Urological Association of South
    Africa. Sun City, South Africa, March 20-24, 2002. Invited presentation.
    
23. Iversen P, Tammela T, Vaage S, Lukkarinen O, Lodding P, Bullnjaa T, Viitanen J, Hoisæter PA,
    Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K. Efficacy and tolerability of
    bicalutamide in early non-metastatic prostate cancer: results of trial SPCG-6. American Society of
    Clinical Oncology (ASCO), 38th Congress May 2002, Orlando Florida. Proceedings 21 (1) abstract
    775.
    
24. McLeod D, See W, Wirth M, Iversen P, Carroll K, Persson B-E. Prostate-specific antigen doubling
    is a valid method of assessing disease progression. American Society of Clinical Oncology
    (ASCO), Annual meeting, Orlando, USA, May 2002. ASCO Proceedings 21(1) abstract 787.
    
25. Wirth M, McLeod D, Iversen P, See W, Morris T, Carroll K. Efficacy of bicalutamide in early,
    non-metastatic prostate cancer by initial stage and grade. ASCO Proceedings 21(1) abstract 2437
    (ASCO abstract book only)
    
26. Iversen P, Tammela T, Vaage S, Lukkarinen O, Lodding P, Bull Njaa T, Viitanen J. Hoisæter PA,
    Lundmo P, Rasmussen, F, Johansson J-E. Efficacy and tolerability of bicalutamide in early nonmetastatic
    prostate cancer: Results of trial SPCG-6. AUA 97th Annual Meeting, Orlando Florida,
    May 2002. J Urol 2002;167 No 4, Supplementum:155 abstract 621.
    
27. Iversen P, Wirth, See W, McLeod D, Morris T, Carroll K. Is the efficacy of hormonal therapy
    affected by lymph node status? Data from the bicalutamide EPC program. AUA 97th Annual
    Meeting Orlando, Florida May 2002. J Urol 2002; 167 No 4, Supplementum:342 abstract 1355.
    
28. Wirth M, McLeod D, Iversen P, See W, Morris T, Carrol K. Efficacy of bicalutamide in early, nonmetastatic
    prostate cancer by initial disease stage and grade. AUA 97th Annual Meeting, Orlando,
    Florida, May 2002. J Urol 2002;167 No 4, Supplementum:345 abstract 1367.
    
29. McLeod D, See W, Wirth M, Iversen P, Carrol K, Persson B-E. Prostate specific antigen doubling
    is a valid method of assessing disease progression. 26th Congress of Société Internationale
    d’Urologie (SIU), Stockholm, Sweden, September 2002. Abstract in BJU Internat 2002; 90 (Suppl
    2):8.
    
30. Norlén B-J, Adami H-O, Bill-Axelsson A, Helgesen F, Holmberg L, Johansson J-E. Radical
    prostatectomy versus watchful waiting in early prostate cancer – results from the Scandinavian
    Prostatic Cancer Group randomized clinical trials. 26th Congress of Société Internationale
    d’Urologie (SIU), Stockholm, Sweden, September 2002. Abstract in BJU Internat 2002; 90 (Suppl
    2):20.
    
31. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson J-E, Norlén BJ, Holmberg L,
    Scandinavian Prostatic Cancer Group number 4. Quality of life after radical prostatectomy or
    watchful waiting. 26th Congress of Société Internationale d’Urologie (SIU), Stockholm, Sweden,
    September 2002.
32. Iversen P. Immediate endocrine therapy in early prostate cancer: Results from the bicalutamide
    Early Prostate Cancer (EPC) Programme. 17th Turkish National Urology Congress. Antalya,
    Turkey, October 2002. Invited presentation.
    
33. Iversen P. SPCG-6. Bicalutamide in the treatment of early prostate cancer. Arctic Urological
    Meeting, Ruka, Finland, February 2003.
    
34. Bill-Axelsson A. A randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in
    Early Prostate Cancer. Arctic Urological Meeting Ruka, Finland February 2003
    
35. Fourcade RO, Klimberg I, See WA, Wirth MP, McLeod DG, Iversen P, Garside L. Bicalutamide
    (Casodex) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free
    survival in early prostate cancer: evidence from a new analysis. EAU Madrid March 13th 2003. Eur
    Urol 2003; Suppl 2 No 1:41.
    
36. Holmberg L, Bill Axel sson A, Adami HO, Johansson J-E, Norlen BJ et al. Results from the
    Scandinavian trial on radical prostatectomy (SPCG4). British Prostate group Annual meeting,
    Edinburgh April 2003.
    
37. Norlén BJ, Holmberg L, Axelsson A, Adami H-O, Johansson J-E, SPCG-4 study group. A
    randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer.
    Edmonton Canada April 2003.
    
38. Holmberg L, Bill-Axelsson A, Adami H-O, Johansson J-E, Norlén BJ, SPCG-4 study group,
    Finland, Iceland and Sweden. A randomised trial comparing radical prostatectomy with watchful
    waiting in early prostate cancer. AUA Chicago April 2003. Abstract 689 in J Urol 2003;169 no 4
    Suppl:179.
    
39. Steineck G, Brändstedt J, Johansson J-E, Adolfsson J, Dickman P, Onelöv E, Norlén B-J,
    Holmberg L. Symptom prevalence at different follow-up times after radical prostatectomy or
    watchful waiting. AUA Chicago April 2003. Abstract 1852 in J Urol 2003;169 no 4 suppl:494-495.
    
40. Klimberg I, See WA, Wirth MP, McLeod DG, Iversen P, Soloway M, Garside L. New analysis
    shows that bicalutamide 150 mg as adjuvant to radical prostatectomy significantly increases
    progression-free survival in early prostate cancer. AUA 98th Annual Meeting, Chicago, April 2003.
    Abstract 696 in J Urol 2003;169 (Suppl):180-181.
    
41. Tyrrell C, See WA, McLeod DG, Wirth MP, Iversen P, Garside L. Adjuvant bicalutamide 150 mg
    significantly improves progression-free survival following radiotherapy for early prostate cancer.
    AUA 98th Annual Meeting, Chicago, April 2003. Abstract 1646 in J Urol 2003;169 (Suppl):440.
    
42. See WA, Wirth MP, McLeod DG, Iversen P. International differences in prostate cancer treatment
    outcomes correlate with clinical stage and pre-treatment prostate-specific antigen level: Results of
    an ongoing, prospective, international trial program. AUA 98th Annual Meeting, Chicago, April
    2003. Abstract 1666 in J Urol 2003;169 (Suppl):445.
    
43. Norlén BJ, Holmberg L, Axelsson A, Adami H-O, Johansson J-E, SPCG-4 study group. A
    randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer.
    Oslo May 2003.
    
44. Brasso K, Johansen JS, Christensen IJ, Teisner B, Price PA, Iversen P. High serum levels of PINP,
    bone alkaline phosphatase, and YKL-40 in patients with advanced prostate carcinoma are
    associated with short survival. Podium presentation American Society of Clinical Oncology
    (ASCO) Chicago June 2003. Abstract 1525 in Proceedings ASCO, 2003; 22:380.
    
45. See W, Wirth M, McLeod D, Iversen P, Garside L, Morris T. Benefits of adjuvant Bicalutamide
    150 mg in high-risk patients after radical prostatectomy or radiotherapy for early prostate cancer.
    American Society of Clinical Oncology (ASCO) Chicago June 2003. Abstract 1576 in Proceedings
    ASCO, 2003; 22:392.
46. McLeod D, See W, Iversen P, Wirth M, Garside L, Morris T. Immediate Bicalutamide 150 mg
    therapy significantly reduces the risk of disease progression in patients with localized prostate
    cancer who would otherwise be candidates for watchful waiting. American Society of Clinical
    Oncology (ASCO) Chicago June 2003. Abstract 1629 in Proceedings ASCO, 2003; 22:405.
    
47. Payne H, Tyrell CJ, See WA, Mcleod DG, Wirth MP, Iversen P, Garside L. Bicalutamide 150 mg
    as adjuvant to radiotherapy significantly increases progression-free survival in early prostate
    cancer. Proceedings of the 45th Annual ASTRO Meeting. Abstract 83 in Int J Radiat Oncol Biol
    Phys 2003;57 (2 suppl):S173.
    
48. Lodding P, Hugosson J, Iversen P, Stranne J. Incidence of inguinal hernia in men with prostate
    cancer (PC): an analysis of 1150 patients from the database of the Scandinavian Prostate Cancer
    Group (SPCG) 6 study. Podium presentation Scandinavian Association of Urology Bergen June
    12th 2003. Abstract 7 in Scand J Urol 2003; 37 Suppl 214:14.
    
49. Fourcade RO, See W, McLeod, Wirth M, Iversen P. Efficacité du bicalutamide 150 mg seul ou en
    adjuvant á traitement á visée curative contre le cancer prostate (CAP) non métastatique : Nouvelle
    analyses avec 5.4 ans suivi médian. 97e Congrès. Association Francaise d’Urologie, Paris,
    November 2003 :39.
    
50. Brasso K, Johansen J, Christensen IJ, Teisner B, Price P, Iversen P. Prognostisk værdi af serum
    P1NP, knoglespecifik alkalisk fosfatase og YKL-40 hos patienter med avanceret cancer prostatae.
    Danish Urological Association November 2003.
    
51. Iversen P, McLeod D, See W, Wirth M, Morris T, Morris C, Carroll K. Bicalutamide (“Casodex”)
    150 mg in patients with early non-metastatic prostate cancer: updated analysis at a median 5.4
    years’ follow-up. XIXth Congress of the European Association of Urology Vienna March 2004.
    Abstract 180 in Eur Urol Suppl 3 (2004) No 2 pp 47.
    
52. Wirth M, Iversen P, McLeod D, See W, Morris C, Morris T, Carroll K. Bicalutamide (“Casodex”)
    150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in
    patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years.
    XIXth Congress of the European Association of Urology Vienna March 2004. Abstract 181 in Eur
    Urol Suppl 3 (2004) No 2 pp 48.
    
53. McLeod D, Iversen P, See W, Wirth M, Carroll K, Morris C, Morris T. Bicalutamide (“Casodex”)
    150 mg as adjuvant to radiotherapy significantly inproves progression-free survival in early nonmetastatic
    prostate cancer: results from the bicalutamide early prostate cancer programme after a
    median 5.4 years’ follow-up. XIXth Congress of the European Association of Urology Vienna
    March 2004. Abstract 182 in Eur Urol Suppl 3 (2004) No 2 pp 48.
    
54. Wirth M, Iversen P, McLeod D, See W, Morris C, Armstrong J, Morris T. Response to second-line
    hormonal therapy following progression on bicalutamide (“Casodex”) 150 mg monotherapy. XIXth
    Congress of the European Association of Urology Vienna March 2004. Abstract 223 in Eur Urol
    Suppl 3 (2004) No 2 pp 58.
    
55. Brasso K, Christensen IJ, Johansen J S, Teisner B, Price A, Iversen P. Variations in serum PINP,
    BAP, and YKL-40 levels after start of treatment for advanced prostate cancer and the relation to
    prognosis. American Society of Clinical Oncology (ASCO) 2004. Proceedings ASCO, 2004; 23. J
    clin Oncol 2004;22(145):4734.
    
56. Iversen P. Bicalutamide 150 mg in addition to standard care in patients with early, non-metastatic
    prostate cancer: Results from the SPCG-6 study at a median follow-up of 5.3 years. American
    Association of Urology, Annual Meeting 2004. San Francisco, California. May 2004. Abstract
    1081. J Urol 2004; 171 (suppl):
57. Iversen P. Endocrine therapy for early prostate cancer - An 5.4 years update of the Bicalutamide
    Early Prostate Cancer Programme. VI Congresso de la Sociedad Mexicana de Oncologia Urologica.
    Acapulco, Mexico, July 2004. Invited presentation.
    
58. Iversen P. Update of SPCG-6. Scandinavian Association of Urology 25th Congress. Göteborg,
    Sweden. June 2005. Invited presentation.
    
59. Iversen P, McLeod D, See W, Morris T, Armstrong J, Wirth M. Adding bicalutamide 150 mg to
    standard care for localised or locally advanced prostate cancer: Results from the largest hormonal
    therapy trial ever conducted in prostate cancer patients, at over 7 years’ follow up. ECCO 13 (The
    European Cancer Conference), Paris, France, October 2005. Presidential Session. European Journal
    of Cancer Supplements 2005; 3 (4): PS2.
    
60. Iversen P. 3rd analysis of SPCG-6 and the Early Prostate Cancer programme. Treatment of early
    prostate cancer in perspective. Svensk Urologisk Förenings Årsmiddag. Riksstämman, December
    2005. Invited presentation.
    
61. Robinson D,Sandblom G, Johansson R, Varenhost E, Hedlund L. PSA and ALP as survival
    predictors for patients with metastatic prostate cancer. European Association of Urology Paris April
    2006. Oral presentation. Abstract 723 Eur Urol Suppl 2006;5(2):203.
    
62. Iversen P, Johansson J-E, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL,
    Tasdemir I, Armstrong J, Morris T on behalf of the Trial 25 study group Efficacy and tolerability of
    bicalutamide in early non-metastatic prostate cancer: latest findings from trial 25 of the early
    prostate cancer programme. European Association of Urology Paris April 2006. Oral presentation.
    Abstract 914 Eur Urol Suppl 2006;5(2):251.
    
63. See W, McLeod DG, Iversen P, Wirth MP, Armstrong J, Navani S. Effect of bicalutamide 150 mg
    on PSA progression in M0 prostate cancer: Results from the Early Prostate Cancer Program.
    American Society of Clinical Oncology (ASCO) annual meeting, Atlanta, May 2006.
    Posterpresentation. Abstract 4624. J Clin Oncol 2006 (suppl); 247s.
    
64. Iversen P, Wirth MP, See WA, McLeod DG, Morris T, Armstrong J. The influence of nodal status
    on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer
    Program at 7.4 years. American Society of Clinical Oncology (ASCO) annual meeting, Atlanta,
    May 2006. Posterpresentation. Abstract 4628. J Clin Oncol 2006 (suppl); 248s.
    
65. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Armstrong J. Delaying metastatic disease
    progression in locally advanced disease – results from the Early Prostate Cancer Program at a
    median follow-up of 7.4 years. American Society of Clinical Oncology (ASCO) annual meeting,
    Atlanta, May 2006. Posterpresentation. Abstract 4629. J Clin Oncol 2006 (suppl); 248s.
    
66. Brasso K, Iversen P, Johansen J. Teisner B, Garno P. Changes in serum P1NP, BAP, CTX-1, and
    YKL-40 following hormonal treatment for metastatic prostate cacinoma are related to survival.
    American Society of Clinical Oncology (ASCO) annual meeting, Atlanta, May 2006. Abstract
    20002. J Clin Oncol; 2006;24 (No 18S):20002.
    
67. Iversen P. Endocrine therapy for early prostate cancer. The Early Prostate Cancer Trial Programme
    at 7.4 years follow-up. XXXVI Kongres Naukowy Polskiego Towarzystwa Urologicznego,
    (Annual meeting of the Polish Urological Society), Poznan, June 2006. Invited lecture
    
68. Iversen P. SPCG-6 and the Early Prostate Cancer Programme - 7.4 years Update. Invited lecture.
    Rapport from Nordic Prostate Cancer Workshop, Urology Summit Meeting: Challenges in the
    Management of Urological Cancers / arranged by Astra/Zeneca Urology in cooperation with EAU.
    Amsterdam July 2006. Web address:
    http//www.astrazeneca.no/azmedica/onkologi/azm070227.html 28.03.2007 or
    http://www.urologiforum.no/Article/518302 28.03.2007
69. Iversen P. Role of antiandrogen monotherapy in the treatment of prostate cancer: Fokus on the
    Casodex (Bicalutamide) EPC Programme. Prostate Cancer Symposium. Hyderabad, India. October
    2006. Invited lecture.
    
70. Iversen P. Role of antiandrogen monotherapy in the treatment of prostate cancer: Fokus on the
    Casodex (Bicalutamide) EPC Programme. Prostate Cancer Symposium. New Dehli, India. October
    2006. Invited lecture.
    
71. Iversen P. Treatment of locally advanced prostate cancer. Does the Early prostate Cancer
    Programme make a difference? Prostate Cancer Symposium. Manchester, United Kingdom,
    October 2006. Invited lecture.
    
72. Iversen P. Treatment of locally advanced prostate cancer. Does the Early prostate Cancer
    Programme make a difference? Prostate Cancer Symposium. Liverpool, United Kingdom, October
    2006. Invited lecture.
    
73. Iversen P. Treatment of locally advanced prostate cancer. Do the EPC and the SPCG-6 make a
    difference? Prostate Cancer Symposium. Kristianstad, Sweden. October 2006. Invited lecture.
    
74. Robinson D, Sandblom G, Garmo H, Johansson R, Stattin P, Varenhorst E. PSA- och ALP-förlopp
    som prognostiska faktorer I SPCG-5 studien. Svenska Läkaselskabets Riksstämma November 2006.
    
75. Iversen P. The Bicalutamide Early Prostate Cancer Trial Programme. Satellite Symposium. At the
    American Society of Clinical Oncology (ASCO) – Prostate Cancer Symposium. A
    Multidisciplinary Approach. Orlando, Florida. February 2007. Invited presentation.
    
76. Hedlund PO, Mikkelsen I, Hahne B, Kihl B for the SPCG-5 study group. Parenteral estrogen vs.
    combined androgen deprivation in the treatment of metastatic prostate cancer. The final evaluation of
    the SPCG study. Podium presentation 26th annual congress of the Scandinavian Association of
    Urology. Abstract 1 Scand J Urol Nephrol 2007;41 Suppl 217:8.
    
77. Pedersen KV on behalf of the Scandinavian Prostatic Cancer Group trial No. IX. SPCG IX – an open
    multicenter trial on intermittent endocrine therapy in patients with locally advanced or metastatic
    prostate cancer. Podium presentation 26th annual congress of the Scandinavian Association of Urology.
    Abstract 2 Scand J Urol Nephrol 2007;41 Suppl 217:8.

(Top)